1. Pink Sheet
  2. >>R&D
  3. >>Clinical Trials

What's Next For Bristol's Opdivo/Yervoy Combination

 
• By Emily Hayes

Updated data from CheckMate 012 of Yervoy/Opdivo in first-line lung cancer bode well for the Phase III CheckMate 227 study, plus other indications, Bristol says.

CHICAGO — Bristol-Myers Squibb Co. has high hopes for its strategy of combining the PD-1 inhibitor Opdivo and the CTLA-4 inhibitor Yervoy in a range of indications, buoyed by updated Phase Ib data from the CheckMate 012 study in first-line non-small cell lung cancer.

The company reported updated data from CheckMate 012 of the combination in treatment-naïve NSCLC on June 4 at the American...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Boosting EU Clinical Trials: EMA Opens Dialogue With Global CRO Group

 
• By Vibha Sharma

The European Medicines Agency’s inaugural bilateral meeting with the Association of Clinical Research Organizations underscores ACRO’s commitment to advancing innovation and its presence in the EU clinical trials ecosystem.

US FDA Rare Disease Hub RISEs After Slow Start

 
• By Michael McCaughan

The first “Rare disease Innovation, Science and Exploration (RISE) meeting to discuss the choice of control arms for studies in small populations will be Sept. 3 after plans were delayed by ongoing changes at the FDA.

Cancer Drug Combos: US FDA Guidance Offers Options Beyond Factorial Trials

 
• By Manas Mishra

Acknowledging the risks and limitations of factorial designs, draft guidance outlines how sponsors might employ external data, such as registries or patient-level real-world data, for combination cancer therapies.

GDPR Clarity For Pharma: Industry Code Nears EU-Wide Approval After Six-Year Journey

 
• By Vibha Sharma

The pharmaceutical industry is edging closer to EU-wide clarity on how the bloc’s data privacy rules can be applied consistently to clinical trials and pharmacovigilance activities.

More from R&D